Press Releases

GW receives Qualifying Notice for approval in Canada for Sativex®

21 December 2005

GW Pharmaceuticals announces that Health Canada, the Canadian regulatory authority, has issued a Qualifying Notice for the approval of Sativex®, a cannabis-based medicinal extract product.... more

Statement In Response To The Verdict Of The Inquest Into The Death Of Mrs Rene Anderson

16 December 2005

During the course of this week, an inquest has taken place in Sheffield into the death of Mrs Rene Anderson. Mrs Anderson, a 69 year old diabetic, died in March 2004. One of the factors in her case, w... more

GW and Almirall Announce European Development and Marketing Agreement for Sativex®

12 December 2005

GW and Almirall Prodesfarma, S.A. (“Almirall”) announce that they have entered into an exclusive agreement for Almirall to market Sativex® in Europe (excluding the UK).... more

UK Named Patient Prescribing for Sativex®

15 November 2005

GW announces that it has been informed by the Home Office that the Drugs Minister, Paul Goggins, has confirmed that Sativex® oromucosal spray, its cannabis-based medicine, may be imported from Canada ... more

Rheumatology Journal Publishes Positive Sativex® Study in Rheumatoid Arthritis

9 November 2005

Rheumatology, the official monthly journal of the British Society of Rheumatology (BSR), today announces the publication of the first study to use a cannabis-based medicine (CBM) for treating rheumato... more

Sativex® to be supplied by Catalonian Government to 600 patients in Spain

6 November 2005

GW Pharmaceuticals is today pleased to announce that it has reached agreement with the Health Department of The Regional Government of Catalonia in Spain to supply Sativex® oromucosal spray, its canna... more

Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis

7 September 2005

The cannabis based medicine, Sativex®, is effective in reducing central neuropathic pain and sleep disturbance in people with Multiple Sclerosis (MS) in a UK study published today in the medical journ... more

Sativex® Launched in Canadian Market by Bayer HealthCare

20 June 2005

GW is pleased to announce that, following the receipt of regulatory approval from Health Canada, Sativex is now available by prescription through Canadian pharmacies as an adjunctive treatment for sym... more

UK Regulatory Update Medicines Commission Confirms Further Clinical Efficacy Data Required

10 June 2005

In December 2004, GW announced that the Committee on Safety of Medicines (CSM), an advisory body to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), had adv... more

Statement Re: Media Comment

6 June 2005

GW notes recent media comment.... more

Misleading US Advertisement - GW Response

19 May 2005

If you are in the United States and are accessing this web page in response to a US advertisement funded by Common Sense for Drug Policy, please note that this advertisement is not endorsed by GW Phar... more

GW Announces Amendments to its Sativex Marketing Agreement

11 May 2005

GW and Bayer Healthcare AG announce certain amendments to their marketing agreement for Sativex in the UK and Canada. The amendments have been made in light of the recent regulatory approval of Sative... more

GW Announces Regulatory Approval of Sativex® in Canada

19 April 2005

GW announces that Sativex® has been granted regulatory approval in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis.... more

Interim Results For The Six Months Ended 31 March 2005

31 March 2005

GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 Mar... more

Appointment of Dr Stephen Wright as Director

23 March 2005

GW is pleased to announce the promotion of Dr Stephen Wright to GW’s Board of Directors with immediate effect.... more

GW Appoints Senior US Experts to Support US Market Entry

28 February 2005

US Founder Investors increase stake with approx $5m additional investment ... more

Preliminary Results for the Year Ended 30 September 2004

19 January 2005

GW Pharmaceuticals announces its Preliminary Results for the year ended 30 September 2004... more

GW Announces Positive Preliminary Results with its Cannabis-based Medicine (Sativex®) in Phase III Cancer Pain Trial

19 January 2005

GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 177 patients with severe cancer pain.... more